Circulating tumor cells and evaluation of targeted therapy effect in EGFR mutation/ALK translocation metastatic non-small cell lung cancer.

Abstract

e19084 Background: Targeted therapies have considerably improved the prognosis of patients with non-small cell lung cancer (NSCLC) ,RESIST criteria was the most often used response assessment method to reflecting the clinical benefits. We propose a non-invasive, folate receptor (FR)–based circulating tumor cell (CTC) detection approach to interpret treatment response of targeted therapy between baseline and follow-up CTC values in EGFR mutation/ALK translocation advanced NSCLC. Methods: CTCs were collected from 4 ml of blood based on negative enrichment by immunomagnetic beads in blood from 51 advanced NSCLC patients before the start of targeted therapy and after one month, three months of therapy. The change of CTCs value, radiological response and patient reported outcome(PRO) were compared. Sequential analyses were conducted to monitor CTC signals during therapy and correlate radiological effects with treatment outcome. Results: CTCs were detected in pretreatment and protreatment blood samples from all...